• AHA
  • ESC
  • ASCO
  • ACC
  • RSNA
  • ISC
  • SABCS
  • AACR
  • APA
  • Archives
株式会社ヘスコインターナショナルは、法令を遵守し本サイトをご利用いただく皆様の個人情報の取り扱いに細心の注意を払っております。


Pemetrexed is as effective against recurrent non-small cell lung cancer as docetaxel but with significantly fewer side effects

Patients with recurrent non-small cell lung cancer treated with pemetrexed have similar survival rates but significantly fewer side effects than patients treated with docetaxel, according to a presentation at the 10th World Congress on Lung Cancer. In earlier clinical trials, pemetrexed improved survival among patients with malignant pleural mesothelioma.

"Alimta [pemetrexed] is emerging as a promising new treatment option for lung cancer patients," said Frances Shepherd, MD, study presenter. "The [pemetrexed] data gathered thus far represent a significant advance and will positively affect the future of treatment for both non-small cell lung cancer and malignant pleural mesothelioma."

The data presented at the Congress Presidential Symposium come from a phase III international trial comparing pemetrexed and docetaxel for patients with recurrent non-small cell lung cancer. The patients in the pemetrexed group had a median survival of 8.3 months compared with 7.9 months for patients in the docetaxel group.

Importantly, the researchers found a difference in the incidence of severe neutropenia (5 percent in the pemetrexed arm and 40 percent in the docetaxel arm), number of patients with neutropenia-related fever, and number of related hospitalizations, as well as fewer drug-related serious adverse events. All of the differences in side effects reached statistical significance.




DOLについて - 利用規約 -  会員規約 -  著作権 - サイトポリシー - 免責条項 - お問い合わせ
Copyright 2000-2025 by HESCO International, Ltd.